Clinical Context
SGLT2 inhibitors have transformed type 2 diabetes management, offering glycemic control alongside weight loss, blood pressure reduction, and remarkable cardiovascular and renal protection. However, the mechanisms underlying their benefits extend beyond simple glucose lowering. Understanding these mechanisms helps explain why SGLT2 inhibitors provide benefits that seem disproportionate to their glycemic effects and informs their use across the cardiometabolic spectrum.
Adipokines—hormones secreted by adipose tissue—play crucial roles in metabolic health. Leptin, primarily known for appetite regulation, also affects insulin sensitivity, inflammation, and cardiovascular function. In obesity, leptin levels rise but leptin resistance develops, creating a state of hyperleptinemia that promotes inflammation and cardiovascular risk. Reducing leptin levels, particularly when done independent of weight loss, suggests direct effects on adipose tissue function rather than simply reflecting fat mass changes.
Enavogliflozin is a selective SGLT2 inhibitor marketed in South Korea. While less studied globally than empagliflozin or dapagliflozin, it shares the class mechanism of inhibiting renal glucose reabsorption. This study examined whether enavogliflozin improves adipokine profiles through mechanisms beyond weight reduction—a finding that would enhance understanding of SGLT2 inhibitor pleiotropic effects.
Study Summary (PICO Framework)
Summary:
In patients with inadequately controlled type 2 diabetes, 24 weeks of enavogliflozin treatment significantly decreased leptin levels, improved insulin resistance, and increased ketone levels independent of weight changes compared to baseline, with only mild metabolic-related adverse effects.
| PICO | Description |
|---|---|
| Population | Adults with inadequately controlled T2DM and elevated leptin/insulin resistance. |
| Intervention | Enavogliflozin (SGLT2 inhibitor) for 24 weeks. |
| Comparison | Baseline metabolic parameters (before-after design). |
| Outcome | Decreased leptin levels independent of weight loss, improved insulin resistance, increased ketone levels. Mild adverse effects only. |
Clinical Pearls
1. Weight-independent adipokine improvement suggests direct adipose tissue effects. If leptin reduction simply reflected fat mass loss, the improvement would correlate with weight change. The finding that leptin decreased independent of weight suggests enavogliflozin directly modifies adipose tissue function—perhaps by reducing adipose inflammation, improving insulin signaling in adipocytes, or shifting adipokine secretory patterns. This represents a pleiotropic effect beyond glucose lowering.
2. Increased ketones reflect the metabolic shift central to SGLT2 inhibitor effects. SGLT2 inhibitors cause glycosuria (glucose loss in urine), which reduces blood glucose and triggers a metabolic shift toward fat oxidation and ketogenesis. Mildly elevated ketones (not ketoacidosis) may actually be beneficial: ketones are an efficient cardiac fuel, may reduce oxidative stress, and serve as signaling molecules with anti-inflammatory effects. The “thrifty fuel hypothesis” suggests this metabolic shift contributes to cardiovascular protection.
3. Improved insulin resistance compounds glycemic benefits. SGLT2 inhibitors lower glucose through a non-insulin-dependent mechanism (renal glucose excretion), but secondarily improve insulin sensitivity by reducing glucotoxicity and lipotoxicity. This creates a virtuous cycle: better glycemic control → reduced insulin resistance → even better glycemic control with less hyperinsulinemia. The insulin-sparing effect may reduce long-term beta-cell stress.
4. This mechanistic study supports the broader SGLT2 inhibitor class story. While cardiovascular outcome trials demonstrate that SGLT2 inhibitors save lives, mechanistic studies like this explain how. Understanding mechanisms helps clinicians apply these drugs rationally, explains why benefits appear in populations beyond diabetes (heart failure, chronic kidney disease), and may guide development of next-generation therapies.
Practical Application
SGLT2 inhibitors offer benefits beyond weight and glucose: When counseling patients about SGLT2 inhibitors, emphasize that benefits extend beyond the scale and HbA1c. Improvements in metabolic health, cardiovascular risk, and kidney function occur through multiple mechanisms. This reframing may improve adherence in patients disappointed by modest weight loss.
Consider SGLT2 inhibitors early in T2DM management: Given their multifactorial benefits—glycemic control, weight reduction, blood pressure lowering, cardiovascular protection, renal protection, and now adipokine improvement—SGLT2 inhibitors should be considered early in T2DM, not reserved for treatment failures. Guidelines increasingly recommend them as first-line add-on to metformin or even initial therapy in appropriate patients.
Monitor for but don’t fear mild ketone elevation: Patients (and some clinicians) may worry about ketones with SGLT2 inhibitors. Mild, stable ketone elevation is expected and likely beneficial. Euglycemic diabetic ketoacidosis (DKA) is rare and occurs with specific triggers (insulin omission, illness, surgery, dehydration). Educate patients about DKA warning signs and sick-day management, but don’t let DKA fear prevent appropriate SGLT2 inhibitor use.
Enavogliflozin’s findings likely extend to the SGLT2 inhibitor class: While this study used enavogliflozin (available primarily in Korea), the mechanism is class-based. Similar adipokine effects have been demonstrated with empagliflozin, dapagliflozin, and canagliflozin. Clinicians can apply these mechanistic insights regardless of which SGLT2 inhibitor they prescribe.
How This Study Fits Into the Broader Evidence
Multiple studies have explored SGLT2 inhibitor effects on adipokines. Empagliflozin has been shown to reduce leptin and increase adiponectin (an anti-inflammatory adipokine). Dapagliflozin reduces visceral fat preferentially over subcutaneous fat, suggesting targeted effects on metabolically active adipose depots. The consistent pattern across agents supports a class effect on adipose tissue metabolism.
The cardiovascular outcome trials (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58) showed SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular death with remarkable speed (benefits emerged within weeks to months). Such rapid effects suggest mechanisms beyond gradual metabolic improvement—hemodynamic effects, ketone-mediated cardioprotection, and reduced cardiac fat may contribute. Adipokine modulation adds another mechanistic layer.
In heart failure (DAPA-HF, EMPEROR-Reduced) and chronic kidney disease (DAPA-CKD, EMPA-KIDNEY) populations without diabetes, SGLT2 inhibitors still provide protection. This demonstrates that benefits aren’t mediated solely through glucose lowering—the pleiotropic mechanisms identified in studies like this explain non-diabetic efficacy.
Limitations to Consider
This is a single-arm, before-after study without a control group—changes could reflect regression to the mean or temporal trends. Sample size and specific population characteristics affect generalizability. Adipokines are surrogate markers; clinical outcomes weren’t assessed. Enavogliflozin has less outcome trial data than empagliflozin or dapagliflozin. The 24-week duration is relatively short for chronic disease assessment.
Bottom Line
Enavogliflozin treatment for 24 weeks improved adipokine profiles (reduced leptin) independent of weight changes in patients with type 2 diabetes, while also increasing ketones and improving insulin resistance. These weight-independent metabolic effects suggest SGLT2 inhibitors have direct beneficial effects on adipose tissue function beyond simple caloric loss. For clinicians, this reinforces that SGLT2 inhibitor benefits extend beyond glucose and weight, supporting their early use in type 2 diabetes for comprehensive metabolic improvement.
Source: Young Sang Lyu, et al. “Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.” Read article here.
